文献速递神经免疫脑血管病头痛与眩晕

评估β-干扰素在多发性硬化中的安全性:系列巢式病例对照研究

Evaluating the safety of β-interferons in MS: A series of nested case-control studies.
PubMed 文献 · Neurology · 2017-05-12

对47种潜在不良事件进行发生率分析,并对至少30例的事件开展巢式病例对照研究,发现既往β-干扰素暴露与卒中、偏头痛、抑郁和血液学异常风险升高相关。

要点

  • β-干扰素暴露与卒中风险升高相关(ORadj 1.83,95% CI 1.16-2.89)。
  • β-干扰素暴露与偏头痛风险升高相关(ORadj 1.55,95% CI 1.18-2.04)。
  • β-干扰素暴露与抑郁和血液学异常风险轻度升高相关。

核心结论

  • 在复发缓解型多发性硬化患者中,β-干扰素与卒中风险增加1.8倍、偏头痛风险增加1.6倍、抑郁和血液学异常风险增加1.3倍相关。

研究设计与样本

  • 共2485例 eligible 患者,77.9%为女性,1031例在随访期间接受β-干扰素治疗;对47种潜在不良事件中至少30例的事件进行巢式病例对照分析,病例按年龄(±5岁)、性别和队列入组年份匹配,最多20名对照。

主要发现

  • 卒中患者既往β-干扰素暴露的调整OR为1.83(95% CI 1.16-2.89)。
  • 偏头痛患者既往β-干扰素暴露的调整OR为1.55(95% CI 1.18-2.04)。
  • 抑郁患者既往β-干扰素暴露的调整OR为1.33(95% CI 1.13-1.56)。
  • 血液学异常患者既往β-干扰素暴露的调整OR为1.32(95% CI 1.01-1.72)。

临床怎么用

  • 在复发缓解型多发性硬化患者使用β-干扰素时,应关注卒中、偏头痛、抑郁和血液学异常的风险信号。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the association between interferon-β (IFN-β) and potential adverse events using population-based health administrative data in British Columbia, Canada. METHODS: Patients with relapsing-remitting multiple sclerosis (RRMS) who were registered at a British Columbia Multiple Sclerosis Clinic (1995-2004) were eligible for inclusion and were followed up until death, absence from British Columbia, exposure to a non-IFN-β disease-modifying drug, or December 31, 2008. Incidence rates were estimated for each potential adverse event (selected a priori and defined with ICD-9/10 diagnosis codes from physician and hospital claims). A nested case-control study was conducted to assess the odds of previous IFN-β exposure for each potential adverse event with at least 30 cases. Cases were matched by age (±5 years), sex, and year of cohort entry, with up to 20 randomly selected (by incidence density sampling) controls. Odds ratios (ORs) with 95% confidence intervals (95% CIs) were estimated with conditional logistic regression adjusted for age at cohort entry. RESULTS: Of the 2,485 eligible patients, 77.9% were women, and 1,031 were treated with IFN-β during follow-up. From the incidence analyses, 27 of the 47 potential adverse events had at least 30 cases. Patients with incident stroke (ORadj 1.83, 95% CI 1.16-2.89), migraine (ORadj 1.55, 95% CI 1.18-2.04), depression (ORadj 1.33, 95% CI 1.13-1.56), and hematologic abnormalities (ORadj 1.32, 95% CI 1.01-1.72) were more likely to have previous exposure to IFN-β than controls. CONCLUSIONS: Among patients with RRMS, IFN-β was associated with a 1.8- and 1.6-fold increase in the risk of stroke and migraine and 1.3-fold increases in depression and hematologic abnormalities.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. de Jong HJI, Kingwell E, Shirani A, et al. Evaluating the safety of β-interferons in MS: A series of nested case-control studies. Neurology. 2017. PMID: 28500224. doi:10.1212/WNL.0000000000004037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。